Furthermore, among the inhaled treatments that have been poorly studied in IPF [94], there is TRK-250, which suppresses the expression of TGF-β1 at the gene expression level in a Phase I, randomized, double-blind and placebo-controlled trial (ClinicalTrials.gov Identifier: NCT03727802). Here, TGFB1 is linked to idiopathic pulmonary fibrosis.